To determine whether a starch solution for volume resuscitation in a flow-based protocol improves circulatory status better than a crystalloid solution, as defined by the need for catecholamines in patients the morning after cardiac surgery, and whether this can be performed without increased morbidity.
D espite controversy over the choice of colloid vs. crystalloid solutions for volume resuscitation of critically ill patients, colloids still are used commonly (1, 2) . It is argued that colloids better maintain or even expand intravascular volume compared to crystalloid solutions and therefore should provide better volume resuscitation for patients who require intravascular volume expansion (3) . Yet, clinically important benefits from the use of colloids have not been found. A meta-analysis on the use of albumin found increased mortality (4) and evoked cries for banning its use (5) , whereas there was no overall evidence of harm in a recent large randomized trial of albumin vs. saline (6) . In meta-analyses in which use of colloid solutions in the form of hydroxyethyl starch (HES) were compared to crystalloid solutions, no advantage for colloids has been found, and there even appeared to be some harm when compared to crystalloid solutions (7) (8) (9) . A recent randomized trial in which use of a 240-molecular weight starch solution for the volume resuscitation of septic patients was compared to use of a crystalloid solution was stopped prematurely because of increased renal failure and a trend toward more deaths in the colloid group (10) . We argue that studies that examine the potential effectiveness of colloid compared to crystalloid solutions need to be flow based so that volume responsiveness can be assessed. This is important because although insufficient vascular volume can be harmful, excess volume can also be harmful (11, 12) . Thus, if colloids are administered to patients who should not have volume expansion, and if the colloid expands intravascular volume better than a crystalloid, then the colloid solution could be more detrimental in those patients.
We identified five basic physiologic principles as being the basis for the proper design of a fluid resuscitation protocol. First, the benefit of volume boluses derives from their potential to increase cardiac output. Second, cardiac output is determined by the interaction of cardiac function as defined by the Frank-Starling relationship and a return function defined by the equation for venous return given by Guyton (13, 14) (Fig. 1 ). These two functions intersect at the right atrial pressure (Pra)/central venous pressure (Pra and central venous pressure are used interchangeably herein) and this value, and not the pulmonary artery occlusion pressure, must always be used to assess the need and efficacy of volume loading of patients (15, 16) . Third, there is a sharp plateau to the cardiac function curve and, once it is reached, further increases in Pra/central venous pressure will not increase cardiac output and may potentially produce harm. Fourth, a bolus of fluid can be used to determine whether the heart is functioning on the ascending or flat part of the cardiac function curve and is thus volume responsive (16) . A large volume is not needed to test responsiveness. Even a 1-mm Hg change in central venous pressure should produce a measurable change in cardiac output when the heart is on the steep part of the cardiac function curve. Fifth, experimental data suggest that colloid solutions that have oncotic values greater than normal plasma can augment cardiac output by changing cardiac function independent of their volume effect, and this potential can be assessed only with measurements of cardiac output and central venous pressure (17) .
We incorporated these five principles in a fluid resuscitation protocol for patients after cardiac surgery. The algorithm was flow based and nurse driven. We chose to study cardiac surgery pa-tients because many patients undergo this procedure and they frequently receive multiple hemodynamic interventions. In our center, almost all are managed with pulmonary artery floatation catheters. Our objective was to determine whether patients treated with an HES solution have better cardiac function than patients treated with just crystalloids in the first 24 hrs after surgery as defined by use of catecholamines between 8:00 AM and 9:00 AM the morning after surgery Our double-blind, randomized trial compared a 10% solution of a 0.45substituted 250-molecular weight HES with predominantly C2 substitution (pentastarch) vs. 0.9% saline solution. This HES has a volume-expanding effect of approximately 1.4 times the volume given and a half-life of 12 to 24 hrs. Predefined secondary end points were total catecholamine use, time using catecholamines, use of blood products, deterioration in renal function based on RIFLE criteria, new use of renal replacement therapy, new atrial fibrillation, development of pneumonia, or mediastinal infections. This latter outcome was based on the results of the trial by McKendry et al (18) and mechanistically could be related to less pulmonary congestion and better cardiac function with the use of a colloid solution. At the conclusion of this CME activity, participants should be better able to evaluate usefulness of colloid infusions in patients after cardiac surgery, compare safety of colloid and crystalloid infusions, and assess complications in patients receiving pentastarch.
PARTICIPANTS AND METHODS
Our study was performed in the intensive care unit (ICU) of the Royal Victoria Hospital in Montreal. The study was approved by the Institutional Clinical Research Review Board and registered with ClinicalTrials.gov (NCT00337805). All patients undergoing elective cardiac surgery were eligible for the study unless informed consent could not be obtained, the treating surgeon did not want the patient included, the patient had a known previous allergic reaction to starches (there were none with this exclusion), or the patient was not going to have a pulmonary artery catheter. Consent was obtained the night before surgery. Patient randomization occurred after surgery and after ruling out the presence of exclusion criteria, which included the absence of a pulmonary artery floatation catheter, the presence of an intra-aortic balloon pump, and the use of the HES solution after the initial priming of the pump. Exclusion criteria before . Q refers to flow (cardiac output or venous return, which are equal in the steady state) and right atrial pressure (Pra) or central venous pressure, which are essentially equal. The intersection of the two curves gives the working cardiac output and working Pra/ central venous pressure. There is a plateau to the cardiac function curve, and Pra above this value do not substantially increase Q (wasted preload). There is a limit to the return function that is produced by collapse of veins as they enter the thorax, and increasing cardiac function in this range does not increase Q (cardiac independent). Only an increase in vascular volume increases flow by shifting the venous return curve to the right. The heart is volume responsive when increases in Pra increase Q into the area of wasted preload (shaded box on the right) (14, 16, 17) . CVP, central venous pressure; VR, venous return. randomization included a request by the surgeon to exclude the patient and, importantly, excessive bleeding immediately after surgery, as discussed in more detail below. Only patients who were in the ICU by 2:30 PM were randomized because the primary end point was the use of catecholamines the next morning. When fluid was clinically indicated after surgery, based on the criteria in the algorithm, randomized patients received up to 1 L of study fluid in 250-mL unmarked bags of either saline or the HES solution according to the study protocol. The bags were prepared in our central pharmacy from stock supplies of saline solution or HES and four bags were put in numbered boxes, which were placed at the patient's bedside for the study and collected the next day to account for bags used. All patients in the study also received 750 mL of the HES in the prime for the cardiopulmonary bypass circuit, as is the standard practice at our institution. Allocation sequence (numbering of the boxes) was performed with a computerized random generator by the central pharmacy, which released the allocation sequence only after the all data were entered and ready for analysis.
Protocol
On arrival to the ICU, the study nurse determined if there were exclusion criteria ( Fig. 2 and Supplemental Figure 1 [see Supplemental Digital Content 1, http://links.lww. com/CCM/A178]). If none was present, then the next step was to determine whether there was excessive drainage from the chest tubes, which was defined as Ͼ200 mL/hr drainage in the first hour, or an initial hemoglobin of Ͻ80 g/L. If blood loss was not excessive, then the patient was randomized. This exclusion was included because an important safety end point was the use of blood products and excessive drainage before administering fluids would have confounded the analysis. One hour was allowed for the drainage to decrease and, during this period, only blood products could be administered. If drainage was controlled within the hour, then the patient was randomized if not excluded; 26 were excluded for this reason. Randomized patients then followed the volume resuscitation protocol. A volume bolus was administered based on four potential triggers: 1) cardiac index (Ci) of Ͻ2.2 L/min/m 2 ; 2) systolic or mean arterial pressure below the prescribed values set by the treating team at the time of admission to the ICU; 3) Pra/central venous pressure of Ͻ3 mm Hg (transducer referenced to 5 cm below the sternal angle); and 4) urine output of Ͻ20 mL/hr. Volume boluses were not administered if the Ci was Ͼ4 L/min/m 2 for these patients were considered to have primarily a vascular resistance problem and were treated with vasoconstrictors, or if Pra/central venous pressure was Ͼ12 mm Hg, because these patients were deemed to be likely on the flat part of the cardiac function curve and not volume responsive (19) . After each bolus of blinded fluid, Pra/central venous pressure and Ci were reassessed ( Fig. 2 ). There were three possible outcomes. If Ci increased by Ͻ0.3 L/min/m 2 and Pra/central venous pressure increased by Ͻ2 mm Hg, then the volume challenge was deemed to be inadequate. If the initial criteria for a volume bolus were still present, then another bolus was administered. If the Ci increased by Ն0.3 L/min/m 2 , whether the Pra/ central venous pressure changed, then the patient was considered fluid responsive and further boluses could be administered if the criteria for a volume bolus were still present. The maximum amount of study fluid that could be administered was 1 L, and after that only saline boluses were used when further volume boluses were deemed necessary. The third condition was the most critical. If Ci increased by Ͻ0.3 L/min/m 2 and Pra/central venous pressure increased by Ն2 mm Hg, then the patient was deemed unresponsive to volume boluses, and hemodynamic abnormalities (i.e., Ci Ͻ2 L/min/m 2 or arterial pressure below the set target) were treated with vasopressors or inotropic agents according to predefined rules (Supplemental Figure 2 [see Supplemental Digital Content 1, http:// links.lww.com/CCM/A178]). Vasopressors included either norepinephrine or epinephrine (no patients received phenylepherine or dopamine) and the inotropic agent was dobutamine; these are collectively called catecholamines. Milrinone was not included as an end point because it was generally started in the operating room to prevent graft spasm and its use was not related to hemodynamic status, nor was it included in the algorithm. Weaning from catecholamines was based on prescribed rules (Supplemental Figure 3 Recordings of standard hemodynamic variables, intravenous drug use, use of blood products, and thoracic drainage were manually transcribed from the medical record for the stay in the ICU or for up to 24 hrs. The creatinine values were followed daily for 5 days, and we also obtained the highest value during the hospital stay and the value before discharge or up to 28 days. Follow-up data collected included incidence of arrhythmia, infections, and return to the ICU, time to discharge, new dialysis, and death in hospital for up to 28 days. For quality assurance of the data, entries were cross-checked with a database that is kept for patients in the ICU and one kept by the cardiac surgery service. 
Randomization and Sample Size
The potential four bags of study fluids (250 mL each) were put in numbered boxes that were stocked by our pharmacy according to a random sequence. All patients randomized were followed up, but the primary analysis was of those who received at least one bag of fluid (modified intention to treat). In a preliminary survey of patients in our unit, 40% meeting the entry criteria of the study were using catecholamines at 8:00 AM. Based on a predicted reduction of catecholamine use from 40% to 25% with the use of an HES solution, and allowing for loss of subjects and a power of 80%, we calculated that we needed 120 patients per arm (240 total) who received fluid.
Statistical Analysis
Baseline characteristics of patients with HES or saline were compared by univariate analysis. Quantitative variables were summarized as mean Ϯ SD, whereas qualitative variables were given as frequency and percentages. Crude measures of effect with 95% confidence intervals (CIs) were calculated, comparing the HES group with the saline group. The number of patients requiring catecholamines, platelets, and fresh-frozen plasma, the number with safety outcomes and complications and with infections, and the number returning to the ICU were analyzed as a relative risk. The sample size was sufficiently large that the total use of catecholamines, platelets, saline, and chest tube drainage, along with the fluid balance and length of stay, could be analyzed as mean differences. No adjustments for multiple comparisons were made after the suggestion of Rothman (20) and Perneger (21, 22) , because these analyses are considered exploratory and hypothesis generating. The number requiring a bolus because of the Ci or the blood pressure indication overall were compared using the chi-square test for trend. The sample size and event numbers were sufficiently large that the Yates correction and Fisher's exact test were not necessary. Lengthof-stay data that were not normal were analyzed using the Wilcoxon signed-rank test.
RESULTS
We screened 1,178 patients ( Fig. 3 ). There were 569 patients who were not approached for consent; of these, 488 were not approached because they had same-day surgery and were not available for consent the night before, because the study nurse was not available, because they had already consented to participation in a competing study, because they were deemed to be too complicated by the patient's surgeon (n ϭ 24), or because one surgeon refused to include his patients (n ϭ 91); 81 patients refused consent. Of the 609 who consented, 346 were not enrolled after surgery. In 211 instances, patients were planed as second cases of the day and consent was obtained as "back-up" patients. Of the remaining 135, 26 were excluded for bleeding, eight were excluded for lack of a pulmonary artery catheter, 15 were excluded because they had an intra-aortic balloon pump, 13 were excluded because they were deemed too sick postoperatively by the surgeon, 14 were excluded because the timing of surgery was changed, eight were excluded because of nursing error, 31 were excluded because they received HES on exit from the operating room and before randomization, and 20 were excluded for other reasons. The remaining 263 patients were randomized and 237 received fluids; 119 received HES and 118 received saline. These 237 comprise the primary set for the intention-to-treat analysis. The other 26 randomized patients did not have a trigger for fluid administration in the first 24 hrs postoperatively. The demographic data and clinical characteristics of the 237 patients who received fluids are given in Table 1 and were similar in both groups. The Parsonnet score, which is a predictor of mortality based on preoperative risk factors, was similar in both groups and predicted a mortality of 2% to 4% (Table 1) (23).
In the HES group, there were 13 (10.9%) patients using catecholamines between 8:00 AM and 9:00 AM the morning after surgery (primary end point) compared to 34 (28.8%) patients in the saline group (relative risk, 0.38; 95% CI, 0.21-0.68; p Ͻ .001) ( Table 2 and Fig. 4 ). The total time using catecholamines was 10.3 Ϯ 12.3 hrs in the HES and 13.8 Ϯ 15.2 hrs in saline patients (mean difference, Ϫ3.5 hrs; 95% CI, Ϫ7.1 to 0.01; p Ͻ .05), and total catecholamine use was 3.4 Ϯ 5.1 mg in the HES and 5.4 Ϯ 10.3 in saline patients (mean difference, Ϫ2.01 mg; 95% CI, Ϫ4.08 to 0.07; p ϭ .06) ( Table 2 ). There were 42 patients (18% of patients who received fluid boluses) in whom the treating team gave HES off protocol: 15 (13%) in the HES group and 27 (24%) in the saline group. Instead of using the intention-to-treat analysis, we compared all cases that received HES, whether assigned to HES or saline, to patients who received only saline; there were 24 HES (19.7%) and 23 saline (25.2%) using catecholamines the morning after surgery, and the benefit of the HES was no longer significant.
Chest tube drainage was greater in the HES group than in the saline group when measured at 24 hrs or sooner (if they departed before 24 hrs) (129 mL; CI, 1-258; p ϭ .049) but not significantly different if fluid loss from the operating room was included or when the total loss in the ICU was included ( Table 2) . Patients allocated to HES received fewer fluid boluses for study triggers in the algorithm and specifically for the indication of Ci Ͻ2.2 L/min/m 2 . There were 43 HES and 68 saline patients who received all four boluses (relative risk, Ϫ0.215; CI, Ϫ0.332 to Ϫ0.088; p Ͻ .001). At 8:00 AM, HES patients had the same Ci and central venous pressure as saline patients, de- spite receiving less catecholamines and less fluid ( Table 2) . ICU lengths of stay were similar in the two groups (median, 24.0 hrs in HES and 24.5 hrs in the saline group) ( Table 2 ). The hospital length of stay was 8.9 Ϯ 5.7 days in HES and 10.9 Ϯ 20.5 days with saline (excluding the four deaths). In a post hoc analysis, we assessed the proportion of patients who were discharged from the ICU at 24 hrs in both groups. As with the catecholamine end point, this value relates to the efficiency of a cardiac surgery ICU. There were 58.9% of HES patients and 50.0% in the saline group who were discharged at 24 hrs, indicating a trend to improved early discharge (relative risk, 8.9%; CI, Ϫ1.8 to 19.3).
The number of patients receiving red blood cells and the total volume were not significantly different in the two groups, nor was the use of platelets and cryoprecipitate. There was a greater number of patients who received fresh-frozen plasma in the HES group (relative risk, 1.98; CI, 1.01-3.90; p ϭ .048).
One patient in each group required new renal replacement therapy. The average creatinine was the same in both groups over the course of the hospital stay (Fig. 5 ). The number of patients with an increase in creatinine over the course of their hospital stay of 50% (equals RIFLE risk category) (24) was similar in the two groups. Only four patients in the HES group and five in the saline group reached RIFLE injury category or higher. There were two deaths in each group. One HES patient died with a cerebral vascular accident, Gram-negative sepsis, and heparin-induced thrombocytopenia on day 5 in the ICU; the Parsonnet score was 18. This patient received acute renal replacement therapy. The second HES patient had Clostridium difficile colitis and died on day 16 postoperatively; the Parsonnet score was 35.5. In the saline group, one died with an ischemic limb; the Parsonnet score was 31. The other had chronic renal failure and died of myocardial dysfunction 76 hrs after surgery; the Parsonnet score was 34.
Complications are listed in Table 3 . The HES group had markedly fewer sternal and pulmonary infections (Fig. 3) . HES patients had less use of cardiac pacing ( Fig. 4 ).
DISCUSSION
With the use of an algorithm based on the measurement of central venous pres-sure and cardiac output, HES solution for early resuscitation in patients after cardiac surgery reduced the use of catecholamines between 8:00 AM and 9:00 AM the morning after cardiac surgery by 62% compared to just the use of saline. In marked contrast to retrospective observational studies (25) and studies in septic patients (10) , this proved that cardiovascular function in HES patients occurred without increased renal dysfunction. The use of a colloid also was associated with a trend toward fewer pneumonia and mediastinal infections than seen for the use of crystalloids alone.
Based primarily on meta-analyses (7, 8, 26, 27) , it has been argued that colloids are no better or even more harmful than crystalloid solutions. Some reports suggest increased mortality and others suggest more blood loss and renal failure. Colloids are most commonly used for routine postsurgical patients in whom mortality is very low, and thus mortality is not a good indicator of the clinical usefulness of colloids in these patients. Physicians use colloids in postoperative patients because there is an evident immediate hemodynamic response (29) , but there are no data to indicate that this has a positive outcome effect. Furthermore, outcomes based on harm have meaning only if there is an indication for the use of colloids.
Our primary end point was the use of catecholamines between 8:00 AM and 9:00 AM the morning after surgery. This seemingly unusual end point is highly relevant in a busy cardiac surgery program because patients must be not using catecholamines before they can be transferred to a step-down bed, and this decision must be made before starting that day. This tends to force a decision and provides an objective end point that reflects hemodynamic stabilization and not just an increase in cardiac output.
Our study was powered on the basis of hemodynamic efficacy for this proof-ofprinciple study, but one would expect that improved hemodynamic function should also affect other clinical outcome measures. McKendry et al (18) found that a flow-directed protocol to optimize circulatory status reduced the incidence of pulmonary and mediastinal infections. We, too, found that use of an HES solution significantly reduced this predefined secondary outcome. Two other cardiac end points are worth noting. There was significantly less use of pacing in HES patients and a trend toward less atrial fibrillation. These are plausible benefits of improved hemodynamics for improved cardiac status, and less pulmonary congestion would result in less load on the right ventricle and reduce triggers for these events. There were also fewer fluid boluses over time in the HES group and especially fewer interventions for a low Ci, which suggests sustained improvement of cardiac function.
In this pilot trial, the time spent in the ICU and time in hospital were not significantly shortened with the use of colloids, but we had little power to detect a difference given the large variance and markedly skewed data. A post hoc analysis of proportions discharged at 24 hrs, which is a crucial time for the flow of new surgical cases, showed a trend toward greater discharge in HES patients (p ϭ .13). If the 9% greater proportion discharged in the HES group than in the saline group (Table 2) was confirmed in a larger trial, it would result in one extra ICU bed per week in a center that sees 1,000 cases per year. We accordingly plan on making this the end point for a larger multicenter trial.
Two major safety concerns with the use of HES are the development of renal dysfunction and increased bleeding (10, 25, 29 -31) . Patients with preexisting renal disease were not excluded, and six in the colloid group and seven in the crystalloid group had chronic renal failure. The mean creatinine concentrations were similar in both groups during the hospital stay, as were the numbers with renal risk development based on RIFLE criteria (Ͼ50% increase in creatinine) (24) . Only one patient in each group required new renal replacement therapy. The creati- nine over time was the same even when saline patients who received HES were included with the HES patients.
Bleeding is more difficult to analyze, and one must be cautious about interpreting chest tube drainage and even the use of blood products as indicating bleeding. There were some patients who lost as much as 5 L from their chest tubes but did not receive blood transfusions, which indicates that hematocrit of this fluid is variable (32) . If a substance such as HES more effectively increases plasma volume than saline, then this will dilute clotting factors and potentially increase bleeding and also lower the international normalized ratio and hemoglobin and potentially trigger transfusions (33) . The higher hydrostatic pressure could also increase transvascular fluid filtration in the lung (34) and chest tube drainage, which might be interpreted as bleeding. A larger sample size would be needed to properly assess blood loss outcomes.
A number of features of our study design may have reduced the risks of harm with the use of HES. Boluses of fluid were administered only for hemodynamic need, and repeated boluses required evidence of an increase in cardiac output. Each bolus was only 250 mL, and the total study fluid was limited postoperative to 1000 mL, although saline boluses could be continued after the study fluids were finished. It is noteworthy that only 36% of HES and only 58% of saline patients received the full 1000 mL, which indicates that not a lot of volume is needed to achieve a hemodynamic benefit. The HES group had a significantly lower fluid balance than the crystalloid group and received half the amount of saline in the postoperative period.
One of our criteria for administering a volume bolus was a central venous pressure of Ͻ3 mm Hg. First, it must be appreciated that pressures are relative to an arbitrary reference point (16) . We reference at a level 5 cm below the sternal angle, as is recommended for physical examination (36) . If the more commonly used midthoracic level is used, then the value would be approximately 3 mm Hg higher (i.e., Ͻ6 mm Hg) (19) . We included this criterion to make sure that reserves of unstressed volume were adequate (16) .
The lack of increased renal dysfunction in our study with the use of an HES of medium molecular size is different from what was observed in a recent study that compared the use of crystalloids to HES for volume resuscitation of sepsis (10) . In volume resuscitation of sepsis, there was a striking increase in renal failure in HES patients, and this resulted in premature termination of the study. This difference may be because subjects in volume resuscitation of sepsis had sepsis, whereas ours did not; however, it is also possible that the difference is attributable to our more restricted use of the HES and identification volume limitation of the heart by the flow-directed protocol, which limited the use of fluid when there was no increase in cardiac output with an adequate increase in central venous pressure. In volume resuscitation of sepsis, the group with the worst outcome received Ͼ250 mL/kg of HES, whereas the largest amount used in our study was 30 mL/kg. In a number of retrospective studies, renal injury was increased in cardiac surgery patients who received HES (25, 31) . Although attempts were made to adjust for baseline differences in one of these studies (25) , these studies are limited by their retrospective design and the lack of a fixed protocol for the use of the HES.
Further support for our argument that colloids must be administered with a careful protocol, which is based on the identification of a flow response, comes from the analysis of all patients who received starch, whether they should have or not, based on the protocol. In this analysis, the colloid advantage was greatly reduced and no longer significant, which supports the argument that these products must be used with respect.
An assessment of cardiac output responsiveness was an essential part of our rationale and protocol. Other studies also have shown that monitoring flow or a surrogate can improve hemodynamic management and outcome in cardiac surgery patients (18, 36) and other conditions (37, 38) . We used a basic pulmonary artery floatation catheter for this purpose, but other devices could have been used. Although use of the pulmonary artery catheter has been criticized (40), in our study there were no complications attributable to the catheter in the ICU, and it is far cheaper than the available less-invasive devices.
CONCLUSION
In conclusion, the use of an HES solution in a flow-based protocol improves hemodynamic performance of patients after cardiac surgery when compared to a crystalloid solution alone, and this resulted in reduced use of catecholamine the morning after surgery, which is a criterion for discharge. This benefit occurred without an increase in renal dysfunction and with some trends toward improvement in other outcome measures. However, there were some trends toward increased use of blood products. This proof-of-principle study indicates that colloid solutions have the potential to improve hemodynamic function without increasing major morbidity if used in appropriate physiologically driven protocols. A larger multicenter trial is needed to determine whether this translates into a clinical end point and without excessive bleeding.
At the conclusion of this CME activity, participants should be better able to evaluate usefulness of colloid infusions in patients after cardiac surgery, compare safety of colloid and crystalloid infusions, and assess complications in patients receiving pentastarch.
